LINTONPHARM
Updated 45 days ago
Building B, No.19 NanXiang 3rd Road, Guangzhou, China
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of becoming the worldwide leader in CD3 bispecific antibody. LintonPharm, in collaboration with Lindis Biotech, is developing Catumaxomab for use in a broad range of cancers globally. Additionally, LintonPharm is developing a next generation bispecific antibody platform to provide a more robust manufacturing and drug design and increased flexibility to individualize the design of each molecule. The current pipeline includes several treatments in development for solid tumors...
We are committed to developing the transformative biotherapeutics with T cell engaging bispecific antibodies
Also known as: LintonPharm Co., Ltd.